Angion Biomedica Corp.
Angion Biomedica Corp. (ANGN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
angn · stock forecast · 4 analysts (3M) · FMP · updated Apr 30, 2024
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Hold
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$1.50
Consensus
$1.50
+50.0% upside
Low
$1.50
Median: $1.5 · Last Close: $1.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.05 | ↑ 5.00% |
1-day model range: $1.04–$1.06. Peak: $1.06 (+5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ANGN · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2022-07-18 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2022-06-30 | Stifel | Downgrade ↓ | Buy→Hold |
| 2022-06-30 | Oppenheimer | Downgrade ↓ | Outperform→Perform |
| 2022-05-23 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2022-04-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-12-10 | Oppenheimer | Maintains | Outperform→Outperform |
| 2021-11-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-10-27 | Stifel | Maintains | Buy→Buy |
| 2021-03-02 | Cowen & Co. | Maintains | Outperform→Outperform |
| 2021-03-02 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Angion Biomedica Corp. (ANGN) stock. Of the recent 12 rating actions, 0 were upgrades and 3 were downgrades. 4 analysts currently cover ANGN.
Analyst Recommendation Trends
ANGN analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast ANGN EPS of $— for the current fiscal year, based on estimates from 0 analysts. The ANGN revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ANGN stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ANGN price target is $1.50 (+50.0% upside), with an analyst consensus of Hold.
The ANGN short-term stock prediction for tomorrow is $1.05 (+5.00%). The ANGN stock price prediction for 2027 estimates an average of $1. The ANGN stock prediction for 2030 projects a range of $0–$0.
Angion Biomedica Corp. trades on NASDAQ under the ticker ANGN. The ANGN stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 25% of covering analysts.
Frequently asked questions
ANGN forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month ANGN price target is $1.50, with a high forecast of $1.50 and a low of $1.50. The median price target is shown in the chart above when available. This implies +50.0% potential upside from the current price of $1.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.